- Home
- RMTI vs INKT Comparison
RMTI vs INKT Comparison
Compare RMTI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- INKT
- Stock Information
- Founded
- RMTI 1994
- INKT 2017
- Country
- RMTI United States
- INKT United States
- Employees
- RMTI N/A
- INKT N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- RMTI Health Care
- INKT Health Care
- Exchange
- RMTI Nasdaq
- INKT Nasdaq
- Market Cap
- RMTI 32.5M
- INKT 75.7M
- IPO Year
- RMTI 1998
- INKT 2021
- Fundamental
- Price
- RMTI $0.98
- INKT $16.54
- Analyst Decision
- RMTI Strong Buy
- INKT Hold
- Analyst Count
- RMTI 2
- INKT 3
- Target Price
- RMTI $4.00
- INKT $37.50
- AVG Volume (30 Days)
- RMTI 449.6K
- INKT 3.0M
- Earning Date
- RMTI 08-14-2025
- INKT 08-12-2025
- Dividend Yield
- RMTI N/A
- INKT N/A
- EPS Growth
- RMTI N/A
- INKT N/A
- EPS
- RMTI N/A
- INKT N/A
- Revenue
- RMTI $97,727,000.00
- INKT N/A
- Revenue This Year
- RMTI N/A
- INKT N/A
- Revenue Next Year
- RMTI $11.16
- INKT N/A
- P/E Ratio
- RMTI N/A
- INKT N/A
- Revenue Growth
- RMTI 12.82
- INKT N/A
- 52 Week Low
- RMTI $0.78
- INKT $4.56
- 52 Week High
- RMTI $5.15
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- RMTI 44.49
- INKT 49.27
- Support Level
- RMTI $1.08
- INKT $16.02
- Resistance Level
- RMTI $1.18
- INKT $20.25
- Average True Range (ATR)
- RMTI 0.09
- INKT 8.31
- MACD
- RMTI -0.01
- INKT -1.23
- Stochastic Oscillator
- RMTI 5.71
- INKT 0.86
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.